Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

 
• By Emily Hayes

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Moscone Center West.
Full results from the pivotal ARAMIS study of Bayer/Orion's darolutamide were presented at the ASCO GU meeting, held at the George R. Moscone Convention Center in San Francisco Feb. 14-16.

More from Anticancer

More from Therapy Areas